CN115697968A - (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法 - Google Patents

(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法 Download PDF

Info

Publication number
CN115697968A
CN115697968A CN202180038252.1A CN202180038252A CN115697968A CN 115697968 A CN115697968 A CN 115697968A CN 202180038252 A CN202180038252 A CN 202180038252A CN 115697968 A CN115697968 A CN 115697968A
Authority
CN
China
Prior art keywords
acid
compound
reaction
salt
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180038252.1A
Other languages
English (en)
Other versions
CN115697968B (zh
Inventor
胡海文
傅鸿樑
陈芬芬
周鑫洁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Original Assignee
Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd filed Critical Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Publication of CN115697968A publication Critical patent/CN115697968A/zh
Application granted granted Critical
Publication of CN115697968B publication Critical patent/CN115697968B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明提供了(S)‑2‑(3S,8S)‑3‑(4‑(3,4‑二氯苄氧基)苯基‑7‑((S)‑1‑苯丙基)‑2,3,6,7,8,9‑六氢‑[1,4]‑二氧杂环己烯并[2,3‑g]异喹啉‑8‑甲酰氨基)‑3‑(4‑(2,3‑二甲基吡啶‑4‑基)苯基)丙酸二盐酸盐合成工艺中的关键中间体(S)‑2‑氨基‑3‑(4‑(2,3‑二甲基吡啶‑4‑基)苯基丙酸甲酯及其盐的制备方法，其采用连续投料的方式，无需柱层析纯化，简化操作，减少损失，提高收率；进一步的，通过成盐纯化的方式获得可稳定储存的高纯度(S)‑2‑氨基‑3‑(4‑(2,3‑二甲基吡啶‑4‑基)苯基丙酸甲酯盐。本发明的制备方法总收率可达到85％以上，目标产物纯度98％以上，异构体含量在0.5％以下，具有工艺稳定性好，产品质量可控的优点，能够应用于工业化生产。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN202180038252.1A 2020-05-28 2021-05-26 (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法 Active CN115697968B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020104816584 2020-05-28
CN202010481658 2020-05-28
PCT/CN2021/095971 WO2021238965A1 (zh) 2020-05-28 2021-05-26 (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法

Publications (2)

Publication Number Publication Date
CN115697968A true CN115697968A (zh) 2023-02-03
CN115697968B CN115697968B (zh) 2024-03-29

Family

ID=78745593

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180038252.1A Active CN115697968B (zh) 2020-05-28 2021-05-26 (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法

Country Status (5)

Country Link
US (1) US20230348390A1 (zh)
EP (1) EP4163271A1 (zh)
CN (1) CN115697968B (zh)
TW (1) TW202210462A (zh)
WO (1) WO2021238965A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117500789A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 一种吡啶硼酸酯的制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1630709A (zh) * 2001-10-18 2005-06-22 百时美施贵宝公司 人胰高血糖素样多肽－1模拟物和它们在治疗糖尿病和相关状况中的应用
CN101253152A (zh) * 2005-09-02 2008-08-27 安斯泰来制药株式会社 作为rock抑制剂的酰胺衍生物
CN101932563A (zh) * 2007-10-08 2010-12-29 莱西肯医药有限公司 (s)-2-氨基-3-(4-(2-氨基-6-((r)-2,2,2-三氟-1-(3＇-甲氧基联苯-4-基)乙氧基)嘧啶-4-基)苯基)丙酸的固体形式及其使用方法
CN102378574A (zh) * 2009-03-30 2012-03-14 转化技术制药公司 取代的偶氮蒽衍生物、药物组合物及其使用方法
JP2012219098A (ja) * 2011-04-01 2012-11-12 Jnc Corp アントラセン誘導体およびこれを用いた有機電界発光素子
CN105492444A (zh) * 2013-07-02 2016-04-13 百时美施贵宝公司 作为rock抑制剂的三环吡啶-甲酰胺衍生物
CN105693554A (zh) * 2016-04-06 2016-06-22 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
US20170301870A1 (en) * 2016-04-13 2017-10-19 Universal Display Corporation Organic electroluminescent materials and devices
TW201925204A (zh) * 2017-11-22 2019-07-01 日商第一三共股份有限公司 稠合三環化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201608195QA (en) * 2014-04-02 2016-10-28 Bristol Myers Squibb Co Biaryl kinase inhibitors

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1630709A (zh) * 2001-10-18 2005-06-22 百时美施贵宝公司 人胰高血糖素样多肽－1模拟物和它们在治疗糖尿病和相关状况中的应用
CN101253152A (zh) * 2005-09-02 2008-08-27 安斯泰来制药株式会社 作为rock抑制剂的酰胺衍生物
CN101932563A (zh) * 2007-10-08 2010-12-29 莱西肯医药有限公司 (s)-2-氨基-3-(4-(2-氨基-6-((r)-2,2,2-三氟-1-(3＇-甲氧基联苯-4-基)乙氧基)嘧啶-4-基)苯基)丙酸的固体形式及其使用方法
CN102378574A (zh) * 2009-03-30 2012-03-14 转化技术制药公司 取代的偶氮蒽衍生物、药物组合物及其使用方法
JP2012219098A (ja) * 2011-04-01 2012-11-12 Jnc Corp アントラセン誘導体およびこれを用いた有機電界発光素子
CN105492444A (zh) * 2013-07-02 2016-04-13 百时美施贵宝公司 作为rock抑制剂的三环吡啶-甲酰胺衍生物
CN105693554A (zh) * 2016-04-06 2016-06-22 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
US20170301870A1 (en) * 2016-04-13 2017-10-19 Universal Display Corporation Organic electroluminescent materials and devices
TW201925204A (zh) * 2017-11-22 2019-07-01 日商第一三共股份有限公司 稠合三環化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAINER HOVORKA ET AL.: "Self-assembly of metallosupramolecular rhombi from chiral concave 9, 9’-spirobifluorene-derived bis(pyridine) ligands", 《BEILSTEIN J. ORG. CHEM.》, vol. 10, pages 432 - 441, XP055871683, DOI: 10.3762/bjoc.10.40 *

Also Published As

Publication number Publication date
WO2021238965A1 (zh) 2021-12-02
TW202210462A (zh) 2022-03-16
EP4163271A1 (en) 2023-04-12
US20230348390A1 (en) 2023-11-02
CN115697968B (zh) 2024-03-29

Similar Documents

Publication Publication Date Title
JP4605606B2 (ja) 軸不斉を有する光学活性な４級アンモニウム塩およびそれを用いたα−アミノ酸およびその誘導体の製造方法
CN104159898B (zh) 用于制备取代的5‑氟‑1h‑吡唑并吡啶类化合物的方法
CN102584893B (zh) 一种草铵膦的制备方法
CN108314639A (zh) 化合物（e）-3-（1-甲基吡咯烷-2-基）-丙烯酸盐酸盐及合成方法
CN115667219A (zh) 一种(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基)丙酸甲酯二酸盐的制备方法
CN115697968A (zh) (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法
CN109897064B (zh) 一种3-吲哚基-3-(磷酸二乙酯基)氧化吲哚化合物的制备方法
CN114989063B (zh) 一种β-卤代吡咯类化合物的合成方法
WO2021242807A1 (en) Methods for preparing methyl (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)propionate and hydrochloric acid salts thereof
CN110028448B (zh) 一种3-羟基-2,3-二氢异喹啉-1,4-二酮化合物的制备方法
CN109574866B (zh) 一种2,6-二甲基苯胺类长链化合物的制备方法
CN113980028A (zh) 一种手性螺环吲哚酮类化合物的制备方法
JPH03118364A (ja) ピリジンカルボン酸誘導体の調製方法
CN117069561B (zh) 一种2-乙基戊酸的制备方法
CN114160206B (zh) 一种催化合成光学活性吲哚类化合物的催化剂、应用、合成方法及光学活性吲哚类化合物
CN109096329B (zh) 一种β-羟基磷酸酯及其不对称合成方法
EP0751141B1 (en) Optically active monophosphino carboxylic acid derivative
CN116675629A (zh) 一种基于天然氨基酸的手性双羧酸四齿双核铑催化剂、合成方法及其应用
CN117069561A (zh) 一种2-乙基戊酸的制备方法
JP3596262B2 (ja) ２，３，４−トリフルオロ−５−トリフルオロメチル安息香酸、そのエステル類及びその製造法
WO2022222473A1 (zh) 阿哌沙班的中间体及制备方法
CN117466773A (zh) 一种艾乐替尼中间体的制备方法
CN111793058A (zh) 一种制备达比加群酯中间体的改良方法
CN112679431A (zh) 一种制备异喹啉酮类化合物的方法
JPH1180076A (ja) ２，３，４−トリフルオロ−５−ヨ−ド安息香酸、そのエステル類及びその製造法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant